×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GLUE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
07:42 am
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $14.00.
Medium
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $14.00.
12/13
07:07 am
glue
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors [Yahoo! Finance]
12/13
07:00 am
glue
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Medium
Report
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
12/11
07:10 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer [Yahoo! Finance]
12/11
07:10 am
glue
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders [Yahoo! Finance]
12/11
07:00 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
12/11
07:00 am
glue
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
High
Report
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
12/5
07:07 am
glue
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/13
09:05 am
glue
Form 4 Monte Rosa Therapeutics, For: Dec 11 Filed by: Hughes Eric A
Medium
Report
Form 4 Monte Rosa Therapeutics, For: Dec 11 Filed by: Hughes Eric A
12/13
09:00 am
glue
Form 3 Monte Rosa Therapeutics, For: Dec 11 Filed by: Hughes Eric A
Medium
Report
Form 3 Monte Rosa Therapeutics, For: Dec 11 Filed by: Hughes Eric A
12/13
07:03 am
glue
Form 8-K Monte Rosa Therapeutics, For: Dec 11
Medium
Report
Form 8-K Monte Rosa Therapeutics, For: Dec 11
12/5
07:04 am
glue
Form 8-K Monte Rosa Therapeutics, For: Dec 05
Low
Report
Form 8-K Monte Rosa Therapeutics, For: Dec 05
11/14
01:24 pm
glue
Form SC 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SC 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/12
10:33 am
glue
Form SC 13G/A Monte Rosa Therapeutics, Filed by: FMR LLC
Medium
Report
Form SC 13G/A Monte Rosa Therapeutics, Filed by: FMR LLC
11/7
07:08 am
glue
Form 10-Q Monte Rosa Therapeutics, For: Sep 30
Low
Report
Form 10-Q Monte Rosa Therapeutics, For: Sep 30
11/7
07:06 am
glue
Form 8-K Monte Rosa Therapeutics, For: Nov 07
Low
Report
Form 8-K Monte Rosa Therapeutics, For: Nov 07
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: